Earnings
US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.
Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”
Major Europe-based consumer health players Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q1 2025 results over the coming weeks.
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.
Along with its 2024 full-year and fourth-quarter results – both down slightly – the Los Angeles-based firm on 19 February announced its board appointed Stephan Gratziani, president since January 2024, as CEO effective 1 May.
Demand returns for Nestle's US dietary supplement brands following supply chain issues, helping the firm's Health Science division post a solid uplift in sales for 2024.
As Norway's Orkla Health searches for a new CEO, the business looks well-placed for future growth after a 15% uplift in sales in 2024.
Major Europe-based consumer health players Haleon, Bayer and Reckitt feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q4 2024 results over the coming weeks.
Direct seller's going to need more than larger number of distributors to generate sustainable growth, analysts say.
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.
Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2024 results over the coming weeks.
Nestlé's US dietary supplement brands are beginning to take back market share a year on from a IT malfunction which has proved harder to recover from than first expected.
An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.
Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.